Dr. Braunstein on Quadruplet Therapies in Multiple Myeloma

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Marc J. Braunstein, MD, PhD, assistant professor in the Department of Medicine at NYU Long Island School of Medicine; course co-director of the Hematology-Oncology System and co-director of the Autologous Stem Cell Transplant Program, NYU Winthrop Hospital of NYU Langone Health’s Perlmutter Cancer Center, discusses quadruplet therapies in multiple myeloma.

The field has had quadruplet therapies for many years in the form of multi-chemotherapy agents and involve cytotoxic agents. Although these combination chemotherapies were not specifically designed for multiple myeloma, but they were effective against aggressive plasms cell clones, explains Braunstein.

Now that more targeted therapies and monoclonal antibodies are available, physicians are able to consider quadruplet therapies for many more patients because these drugs are much more tolerable since they are targeted.

As such, research efforts are now focused on taking the monoclonal antibodies, which have been approved for use in the second- or third-line setting, and using them in combination with standard triplet regimens up front for myeloma, concludes Braunstein.